La cadena de opciones muestra datos clave de las opciones de acciones de Johnson & Johnson a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Johnson & Johnson..

Johnson & Johnson (NYSE:JNJ) Bolsa, Cadena de Opciones

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Johnson &amp; Johnson reportará ganancias del cuarto trimestre. Analiza sus ingresos, expansión de Spravato y opiniones de analistas clave.

Johnson &amp; Johnson (JNJ) reportará ganancias del 4T: ¿Qué opinan los analistas?

IBKR

NFLX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: ABT, NFLX, PG, IBKR y JNJ.

5 acciones en el foco este miércoles: ABT, NFLX, PG, IBKR y JNJ

Dividends

AMGN

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

Descubre las acciones del Dow Jones con los rendimientos por dividendos más altos para 2025. Conoce estrategias populares.

Acciones con mayores dividendos del Dow Jones: Las mejores opciones para 2025

Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Friday announced topline results from Phase&nbsp;3b&nbsp;APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">response to standard therapies</a>.
The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44644676/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-an" rel="noreferrer noopener">compared to placebo</a>.
In the Phase&nbsp;3b&nbsp;APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims" rel="noreferrer noopener">US Judge Rejects Another Johnson &amp; Johnson Attempt To Use Bankruptcy For Talc Cancer Claims</a>
Data were consistent with the well-established safety profile of Tremfya&nbsp;with no new safety signals identified.
APEX is a Phase&nbsp;3b&nbsp;study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya&nbsp;on inhibition of structural damage in patients with active PsA.
Results from the APEX study are being prepared for presentation at upcoming medical congresses.
<h2 class="wp-block-heading">Johnson &amp; Johnson Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson &amp; Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson &amp; Johnson, the 200-day moving average sits at $156.5, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $155.82. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/04/44647720/matador-resources-sells-eagle-ford-assets-announces-potential-buybacks" target="_blank" rel="noreferrer noopener">Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

General

Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

TREMFYA&#xAE; demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study
Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA&#xAE; as a first-line treatment option for patients with active psoriatic arthritis
SPRING HOUSE, Pa., April 4, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the TREMFYA&#xAE; (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1

Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some <a href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-addresses-the-threat-to-national-security-from-imports-of-timber-lumber-and-their-derivative-products/">notable exemptions</a> to the steep levies.&nbsp;
Here's a look at which products and sectors are excluded <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44626421/trumps-reign-of-tariffs-unleashes-d-day-on-wall-street-analyst-warns-of-stagflation-risk">from the reciprocal tariffs:&nbsp;</a>
Semiconductors: Semiconductors were exempted from the sweeping new tariffs due to their critical role in many technologies. However, the sector was deep in the red in Thursday's trading with shares of Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) down 6.78% and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) down 3.69%.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely&nbsp;</a>
Pharmaceuticals: Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry that had been under pressure following the president's prior comments suggesting a 25% tariff on pharmaceutical imports.&nbsp;
"The United States can no longer produce enough antibiotics to treat our sick," Trump said Wednesday. "We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn't be able to do it."
Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) both in the green in mid-morning trading. 
Lumber: Lumber is another product excluded from Trump's tariff plan, for now. The administration said it is investigating how reliance on imported lumber impacts national security and economic stability. Exemptions have been granted to avoid immediate disruptions in supply chains critical to construction and defense in the meantime.&nbsp;
Gold, Copper: Certain metals and minerals including copper, gold and others not found in the U.S. were also exempted from the reciprocal tariff plan.&nbsp;
Gold dropped more than 3%, falling below $3,060 per ounce on Thursday after touching a new record high above $3,160. The SPDR Gold Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), tracking the price of gold, was down only slightly, bucking the broader market declines.&nbsp;
Energy: Oil, gas and refined products imports were exempted from the sweeping new reciprocal tariffs, the White House said on Wednesday.&nbsp;
Shares of the United States Oil Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) fell 7.8% on Thursday, however, as the sweeping tariff plan could threaten global demand.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Photo: Shutterstock/Alones

Government

Specialty ETFs

Commodities

Politics

Global

Economics

Movers

Tech

ETFs

ABBV

ASML

AVGO

Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

For many investors, dividend-focused <a href="https://in.benzinga.com/25/03/44565770/30-year-old-with-65k-in-stocks-sparks-debate-focusing-mostly-on-etfs-but-now-betting-on-bonds-small-caps-and-international-plays">stocks</a> and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day <a href="https://in.benzinga.com/personal-finance/25/02/43768530/should-married-couples-split-expenses-dave-ramsey-says-no-youre-married-not-roommates">expenses</a>, or even finance small luxuries like annual vacations.
While some aim for significant <a href="https://in.benzinga.com/personal-finance/25/03/44518501/20-year-old-university-student-wants-help-with-buying-dividend-stocks-whats-the-best-way-to-start-reddit-weights-in">dividend</a> payouts to replace their salary, others are happy with modest but constant returns that offer a little extra financial freedom.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
This is the case of a Reddit user who is exploring this approach. With $30,000 to invest, he's seeking long-term dividend stocks that can grow over the next 20 years until retirement. While he already holds dividend-paying stocks like Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Walt Disney&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), he wants to expand his portfolio for stability and future income, even if it's just enough to cover yearly vacations.
&#8220;I currently have some stocks that give out dividends (Apple, Disney) but I&#8217;m looking for others. Long-term stability, that my wife and I can use the dividends as another form of income say in 20 years. Even if it&#8217;s just enough to pay for a yearly vacation here or there. Any thoughts on good companies to choose from?&#8221; he asked.
Let&#8217;s break down the Redditors&#8217; advice received in the comment section.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Where to Invest $30,000 to Generate Enough Income to Cover Yearly Vacations? Reddit Answers</h2>
Put the Money in an ETF
Several commenters recommended Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) as a core holding because of its dividend yield, historical growth, and the low-risk, diversified exposure it offers investors.
&#8220;Go all in SCHD. Low risk, nice 3.5% starting yield and it will just keep growing,&#8221; a commenter said.
Reinforcing the idea that SCHD fits the poster&#8217;s long-term stability and dividend payout need, this Redditor also suggested he goes with SCHD: &#8220;Since you want some growth and decent payout, SCHD is a great option. 3.5% dividends and 11% growth over the last 10 years each year.&#8221;
&#8220;I would stick with S&amp;P 500 ETFs being young. Put it in a self-direct investment retirement account to avoid taxes,&#8221; a comment reads.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Consider High-Yield Dividend Stocks and Trusts
Several commenters suggested higher-yield assets that would generate higher payouts for the investor in the long run.
&#8220;If you want higher yield stocks check: [Verizon Communications (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>)], [AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)], [Realty Income Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/o#NYSE">O</a>)], [Altria Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>)], [British American Tobacco (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>)],&#8221; a Redditor recommended.
A commenter mentioned United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) as a great pick since the company seems to start focusing on higher profit margin areas.
&#8220;UPS pays a solid dividend and the share price has been beaten down a lot on the news that they are reducing Amazon deliveries to focus on higher profit margin areas,&#8221; he said.
Suggesting a very detailed portfolio allocation, this Redditor mentioned several ETFs and individual stocks that he considers would help the poster reach his dividend and growth goals.
&#8220;[Vanguard S&amp;P 500 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/voo#NYSE">VOO</a>)] $5,000, 1.25% dividends. Do [dividend reinvestment plan] SCHD $5,000, 3.5% dividends. Do [dividend reinvestment plan], [JPMorgan Equity Premium Income ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jepi#NYSE">JEPI</a>)], [JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jepq#NASDAQ">JEPQ</a>)​] ($5,000), 8% combined dividends. Do [dividend reinvestment plan] [Old Republic International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ori#NYSE">ORI</a>)] $2,000, 3% dividends. Do [dividend reinvestment plan] [Waste Management (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wm#NYSE">WM</a>)] and [Automatic Data Processing (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adp#NASDAQ">ADP</a>)] ($3,000), 2% average dividend. Do [dividend reinvestment plan] [Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)] and [Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>)] $2,000, 4.75% average dividend. Do [dividend reinvestment plan] [JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>)] and [UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)] $2,000, 2% average dividends. Do [dividend reinvestment plan] AAPL and [Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>)] $2,000. [The Coca-Cola Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)] and MO $2,000, 5% average dividends. Do [dividend reinvestment plan] JPM or [American Express (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>)] $2,000. JPM has good potential growth,&#8221; the suggestion says.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AAPL

JEPI

JEPQ

MSFT

SCHD

Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts

13 analysts have expressed a variety of opinions on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.85, along with a high estimate of $181.00 and a low estimate of $152.00. Observing a downward trend, the current average is 1.94% lower than the prior average price target of $170.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627702_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Johnson &amp; Johnson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$171.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Discovering Johnson &amp; Johnson: A Closer Look</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 5.26%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin excels beyond industry benchmarks, reaching 15.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Johnson &amp; Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 13 Analyst Ratings Have To Say About Johnson & Johnson

Shares of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are trading higher on Wednesday. <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">Yesterday, they were down more than 7.5%</a>.  Analysts attribute the move lower to the company's announcement that its pending acquisition of Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) will dilute its earnings.
But the sell-off may have ended, and there is a good chance Johnson &amp; Johnson rallies. This is why our team of trading experts has made it our Stock of the Day.
You can see on the chart below that the selloff ended when the shares reached the $153 level. This wasn't a coincidence. This price level was resistance in November. Price levels that had been resistance converting into support is a frequent occurrence in the financial markets.
It is due to investor and trader psychology.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png" alt="" class="wp-image-853722" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4.png 1615w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44609851/from-seashells-to-satoshi-why-cryptocurrency-is-the-next-natural-evolution-of-money">From Seashells To Satoshi: Why Cryptocurrency Is The Next Natural Evolution Of Money</a>
Some people who sold Johnson &amp; Johnson around $153.00 thought they made a good decision to sell when the price trended lower after. But when the resistance was broken in February, many of these unhappy sellers second-guessed themselves.
Some believed their decision to sell was a mistake and vowed to return their shares. But they would only do so if they could eventually get them at the same price they were sold for.
As a result, when the shares fell to around $153 yesterday, these formerly happy sellers entered the market as buyers. There were so many of them that it put a floor beneath the price. It created support at the same price that had been resistance.
Johnson &amp; Johnson may reverse and move higher.
Some of the buyers who formed this support may become concerned that they will be outbid. They may think there are others who would be willing to pay higher prices than they will, and they know that these are the sellers who will go to them.
Because of this, they increase their bid prices to get ahead of other buyers. Other concerned buyers could see this, and raise their bid prices to get ahead of others as well.
This dynamic could result in a bidding war that forces Johnson &amp; Johnson into an uptrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44607188/arthur-hayes-predicts-bitcoin-to-hit-250000-by-end-of-year">Arthur Hayes Predicts Bitcoin To Hit $250,000 By End Of Year</a></li>
</ul>
Image: Shutterstock

Technicals

ITCI

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended

Guggenheim analyst Vamil Divan reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Neutral.

Guggenheim Reiterates Neutral on Johnson & Johnsonto Neutral

-ReutersAdvances Company's industry-leading portfolio in mental health with addition of CAPLYTA&#xAE; (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults
sNDA submitted to U.S. FDA for CAPLYTA&#xAE; as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care for most common depressive disorders
Addition of CAPLYTA&#xAE; strengthens J&amp;J's robust lineup of therapies with $5 billion+ potential in peak year salesi, further solidifying sales growth above analyst expectations now through the remainder of the decade
Acquisition also includes promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer's disease-related psychosis and agitation
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson &amp; Johnson and will operate as a business unit within Johnson &amp; Johnson Innovative Medicine.
"At Johnson &amp; Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson &amp; Johnson. "We are excited to officially welcome the talented Intra-Cellular Therapies team to the Company, and we look forward to working together as we realize our ambition of becoming the number one neuroscience company worldwide."
With this acquisition, Johnson &amp; Johnson adds CAPLYTA&#xAE; (lumateperone) to its robust portfolio of differentiated medicines. CAPLYTA&#xAE; is a once-daily oral therapy approved to treat adults with schizophrenia, as well as the first and only U.S. Food and Drug Administration (FDA)-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate. In February 2025, Intra-Cellular Therapies announced that the U.S. FDA accepted its supplemental new drug application for CAPLYTA&#xAE; as an adjunctive treatment for adults with major depressive disorder (MDD). The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements Johnson &amp; Johnson's current areas of focus.
"We are focused on investing in what we believe is the future of innovation across our targeted therapeutic areas, including neuroscience," said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson &amp; Johnson. "We are pleased to finalize this acquisition, which serves as a strategic near- and long-term growth catalyst for Johnson &amp; Johnson, and we look forward to working together to continue transforming treatment and patient care for some of today's most debilitating neuropsychiatric and neurodegenerative disorders."

Johnson & Johnson Closes Intra-Cellular Therapies Acquisition; Expects Deal To Dilute Adj EPS By ~$0.25 in 2025

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&amp;P 500 added nearly 0.4%, finishing at 5,633.07, while the Dow edged down 0.03% to 41,989.96. Market optimism was <a href="https://in.benzinga.com/news/earnings/25/04/44591098/nasdaq-surges-1-us-construction-spending-rises-in-february">supported by a 0.7% rise in U.S. construction spending</a> for February. Even so, uncertainty persists as President Donald Trump&#8217;s &#8220;Liberation Day&#8221; moves put <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44598088/trumps-liberation-day-creates-major-uncertainty-for-big-tech-analyst-dan-ives-says">pressure on tech stocks</a>.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Newsmax Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>)
Newsmax shares soared by a whopping 179.01%, closing at $233. The stock&#8217;s intraday high was $265, with a low of $114.22. This comes after the conservative cable news network went public at $10 per share and quickly surged over 500% on its first day of trading. The stock&#8217;s 52-week high and low stand at $265 and $14, respectively. The stock slipped more than 18% in after-hours trading.
Newsmax&#8217;s public debut highlights its rapid growth as the fourth-largest cable news channel, with CEO Christopher Ruddy positioning it as a <a href="https://in.benzinga.com/trading-ideas/movers/25/04/44593007/newsmax-stock-soars-more-than-100-as-ipo-momentum-continues-whats-going-on">high-growth network</a> amid rising conservative viewership and investor interest.
Waton Financial Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>)
Waton Financial shares skyrocketed by 396.25%, closing at $19.85. The stock&#8217;s intraday high and low were both at $19.85, with a 52-week high and low of $19.85 and $4.05, respectively. This surge followed the company&#8217;s announcement of the pricing of its initial public offering of an aggregate of 4,375,000 ordinary shares at a public offering price of $4.00 per share. 
See Also: <a href="https://benzinga.com/analyst-ratings/price-target/25/04/44587443/blackberry-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call" target="_blank" rel="noreferrer noopener">BlackBerry Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
Johnson &amp; Johnson Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)
Johnson &amp; Johnson shares tumbled by 7.59%, closing at $153.25. The stock&#8217;s intraday high was $161.81, with a low of $153.13. This drop came after a U.S. bankruptcy court <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">rejected</a> subsidiary Red River Talc&#8217;s request to approve its prepackaged bankruptcy plan. The stock&#8217;s 52-week high was $169.99 and low at $140.68. 
Hims &amp; Hers Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)
Hims &amp; Hers Health shares spiked by 5.08%, closing at $31.05. The stock&#8217;s intraday high was $33.70, with a low of $28.76. The company announced that it will offer Eli Lilly And Co's Zepbound <a href="https://in.benzinga.com/25/04/44593851/hims-hers-health-stock-jumped-tuesday-afternoon-what-happened">through its Telehealth platform</a>, leading to a surge in its stock price. The stock&#8217;s 52-week high and low are $72.98 and $11.20, respectively. The shares slipped over 3% in the after-hours trading.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares rose by 3.59%, closing at $268.46. The stock&#8217;s intraday high was $277.45, with a low of $259.25. Deepwater Asset Management&#8217;s Gene Munster warned investors of disappointing Tesla delivery numbers for the first quarter, predicting that the coming months could be even more challenging. The stock&#8217;s 52-week high was seen at $488.54 and low at $138.80. 
Benzinga Edge Stock Rankings show Tesla Momentum in the 90th percentile and Growth in the 67th percentile. Wondering how Rivian compares? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="694" height="106" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16.png" alt="" class="wp-image-852317" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16.png 694w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16-300x46.png 300w" sizes="(max-width: 694px) 100vw, 694px" /></a></figure>
Photo: Shutterstock
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://benzinga.com/markets/equities/25/04/44578839/trumps-25-tariff-on-imported-vehicles-could-shatter-detroits-auto-economy-warns-business-leaders">Trump&#8217;s 25% Tariff On Imported Vehicles Could Shatter Detroit&#8217;s Auto Economy, Warns Business Leaders: &#8216;It Will Hurt Hardworking Americans&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NMAX

TSLA

Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition; To Complete Intra-Cellular Acquisition Around April 2, 2025

Johnson &amp; Johnson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its <a href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims">prepackaged bankruptcy plan</a>.
What To Know: U.S. Bankruptcy Court Judge Christopher Lopez rejected Johnson &amp; Johnson&#8217;s prepackaged bankruptcy plan on Tuesday, sending shares of the pharmaceutical giant tumbling. 
The plan was designed to resolve talc-related cancer claims, which Johnson &amp; Johnson argues are baseless and fueled by plaintiff lawyers and outside investors. The settlement was supported by the overwhelming majority of claimants, according to Johnson &amp; Johnson.
&#8220;The disclosures made under oath in the Red River bankruptcy affirmed that the talc litigation is a plaintiff-lawyer driven fake tort, premised on junk science and fueled by third party litigation financing including from foreign sovereign wealth funds. Consequently, the Company has no intent to settle or pay plaintiff lawyers on such meritless claims,&#8221; the company said.
Johnson &amp; Johnson had previously set aside $7 billion for legal costs, but now plans to reverse that decision and fight the lawsuits in court. 
Johnson &amp; Johnson's legal team stated that the ruling allows a few law firms with "financially conflicted motives" to block what they claim was a fair settlement. The company noted that it has won 16 of the last 17 ovarian cancer cases and will continue its defense in the traditional court system.
The rejected bankruptcy plan is the latest in a series of attempts by Johnson &amp; Johnson to limit its liability in the ongoing talc-related litigation. The Department of Justice previously argued that the company's bankruptcy maneuver was a bad-faith effort to shield itself from claims without fully entering bankruptcy. Despite increasing its settlement offer to $9 billion in September, the legal battle continues, contributing to investor concerns and the stock's decline.
JNJ Price Action: Johnson &amp; Johnson shares were down 7.58% at $153.29 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0401"><img loading="lazy" decoding="async" width="1024" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01153625/Screenshot-2025-04-01-at-15.35.59-1024x506.png" alt="" class="wp-image-852002" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01153625/Screenshot-2025-04-01-at-15.35.59-1024x506.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01153625/Screenshot-2025-04-01-at-15.35.59-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01153625/Screenshot-2025-04-01-at-15.35.59-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01153625/Screenshot-2025-04-01-at-15.35.59.png 1533w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/04/44593138/tesla-q1-deliveries-preview-analysts-forecast-377k-but-kalshi-traders-predict-a-miss">Tesla Q1 Deliveries Preview: Analysts Forecast 377K, But Kalshi Traders Predict A Miss</a></li>
</ul>
Image via Shutterstock.

Johnson & Johnson Stock Is Tumbling Tuesday: What Going On?

WIIM

Johnson & Johnson shares are trading lower after a Federal Judge rejected the company's subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.

Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the <a href="https://www.benzinga.com/topic/tariffs">Trump administration on Wednesday.</a>
On Tuesday, a Washington Post report suggested the administration is considering a sweeping 20% tariff on most of the $3 trillion in annual imports.
Survey data showed that goods-producing businesses had been front-loading purchases ahead of the expected tariffs by the end of first quarter, with inventory levels rising and input cost pressures<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44588076/us-manufacturing-slips-into-contraction-as-tariff-driven-costs-hit-near-3-year-high"> hitting a three-year high.</a>
Major indexes showed little movement by midday in New York, with the S&amp;P 500 and Nasdaq 100 posting modest gains.
Notably, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), and Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) each jumped around 6% as investors viewed them as potential winners from auto-related tariffs. 
Reports last week highlighted that all three manufacture vehicles entirely in the U.S., giving them a competitive edge over peers like Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>).
Treasuries climbed as yields fell, and gold took a breather after hitting a record $3,122 per ounce. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose more than 3% to over $85,000, marking its strongest session in three weeks.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,398.82</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,625.05</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,015.97</td>
<td>0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,051.95</td>
<td>0.1 %</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.3% up to $560.83.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $419.37.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $471.29.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% higher to 199.82.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.3%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) fell over 5%, on track for the worst day since late March 2020. The decline followed a ruling from the U.S. Bankruptcy Court for the Southern District of Texas, which rejected the proposed prepackaged bankruptcy plan of its subsidiary, Red River Talc.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) fell to the lowest level since late August, after Jefferies downgraded the stock from &#8216;Buy&#8217; to &#8216;Hold&#8217; and reduced its price target from $20.00 to $12.00.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) rallied 26.5% after completing the spin-off of Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>). </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44589523/trumps-liberation-day-tariff-plan-could-ignite-global-trade-shakeup-betting-markets-price-in-the-pain">Trump Tariffs Could Ignite Global Trade Shakeup: Betting Markets Price In Pain</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

$BTC

ANGI

LCID

RIVN

Select Sector SPDR-Consumer Discretionary

Wall Street Inches Up Ahead Of Tariff Day: What's Driving Markets Tuesday?

The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and strained supply chains as the U.S. economy braces for the impact <a href="https://www.benzinga.com/news/global/25/04/44585626/trump-aides-draft-sweeping-20-tariffs-on-at-least-most-imports-report">of &#8220;reciprocal trade tariffs.&#8221;</a>
On Tuesday, the Institute for Supply Management revealed its closely watched Manufacturing Purchasing Managers' Index dropped back into contraction territory after two months of marginal expansions, slipping from 50.3% in February to 49% in March. 
<h3 class="wp-block-heading">Demand Drops, Costs Spike</h3>
The ISM's March data showed a troubling divergence, further bolstering the risk of entering a stagflation environment: while demand indicators weakened, input costs surged.
The Prices Index rose sharply to 69.4% from 62.4% in February, its highest level since June 2022. The acceleration was primarily attributed to increased tariffs, which companies are rushing to circumvent.
"Prices growth accelerated due to tariffs, causing new order placement backlogs, supplier delivery slowdowns and manufacturing inventory growth," said Timothy Fiore, chair of ISM's Manufacturing Business Survey Committee.
Meanwhile, new orders—a proxy for demand—sank to 45.2% from 48.6%, the lowest reading since August 2024. 
The employment index dropped to 44.7%, the weakest since September 2024, and production fell to 48.3% from 50.7%.
<h3 class="wp-block-heading">Why Are Input Prices Rising This Fast?</h3>
The spike in input costs is largely driven by firms stockpiling inventories to avoid future tariffs. All four components of ISM's inputs measure—prices, supplier deliveries, inventories and imports—registered expansion in March, a rare occurrence when demand is simultaneously falling.
Fiore said inventories are rising not from optimism, but from a "temporary move to avoid tariffs" and are expected to decline once the trade environment stabilizes.
The Backlog of Orders Index fell to 44.5% from 46.8%, indicating companies are burning through old orders without replenishment. Meanwhile, the Imports Index barely stayed in growth territory at 50.1%, down from 52.6%, reflecting reduced sourcing activity.
<h3 class="wp-block-heading">Are Businesses Losing Confidence?</h3>
The contraction in ISM's March data contrasts with the slightly more upbeat tone of S&amp;P Global's manufacturing PMI, which was revised up to 50.2 from 49.8, signaling tepid expansion. Yet, beneath the surface, the cracks are also evident in that survey.
"The strong start to the year for U.S. manufacturers has faltered in March," said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence. He said the early-year boost from improved optimism and tariff-front-running is fading, as production and order books deteriorate.
Williamson noted that "tariffs were the most cited cause of factory input costs rising in March," and the current pace of cost inflation is the highest since August 2022. 
He flagged a sharp deterioration in supply chains, with delivery delays now the worst since October 2022.
"A key concern among manufacturers is the degree to which heightened uncertainty resulting from government policy changes, notably in relation to tariffs, causes customers to cancel or delay spending, and the extent to which costs are rising and supply chains deteriorating in this environment,&#8221; he said.
"Data in the coming months will provide important insights into how the inflationary aspects of policies such as tariffs balance out against any benefits to U.S. producers,&#8221; he added.
<h3 class="wp-block-heading">Market Reactions</h3>
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flipped to losses on Tuesday, down 0.8% by 10:20 a.m. ET. 
The tech-focused Nasdaq 100 – tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – slipped 0.5%, while the Dow Jones Industrial Average lost 1%, weighed down by declines in blue-chip names across healthcare, financials and industrials.
Among mega-cap stocks, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plunged more than 4% after a judge blocked its proposed $10 billion settlement tied to talc-related lawsuits, prompting the company to unwind $7 billion in previously set aside reserves.
In fixed income markets, bond yields fell as demand for Treasuries picked up, reflecting a risk-off shift. The yield on the 10-year Treasury dropped 8 basis points to 4.1%.
Gold prices inched 0.2% higher, further extending record highs. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was up by 0.5%. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44572838/treasury-bonds-have-lost-50-in-5-years-yet-reversal-signals-emerge-in-q1-could-tariffs-actually-push-tlt-higher">Treasury Bonds Have Lost 50% In 5 Years, Yet Reversal Signals Emerge In Q1: Could Tariffs Actually Push TLT Higher?</a></li>
</ul>
Photo: Shutterstock

US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High

A U.S. bankruptcy court in Texas has rejected Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan. The company said the plan included one of the largest settlements in mass tort bankruptcy history and was <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">backed by most claimants</a>.
In October 2024, the  Department of Justice&#8217;s unit argued that Johnson &amp; Johnson&#8217;s latest bankruptcy maneuver is a bad-faith attempt to shield itself from billions in personal injury claims without actually entering bankruptcy.
Instead of appealing the decision, Red River Talc will return to the court system to fight what it calls baseless <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44576950/johnson-johnson-to-return-to-tort-system-to-defeat-meritless-talc-claims" rel="noreferrer noopener">talc-related lawsuits</a>.
The company claims that disclosures during the bankruptcy process confirmed the litigation is driven by plaintiff lawyers, based on flawed science and funded by outside investors, including foreign sovereign wealth funds.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41466839/justice-departments-trustee-program-alleges-johnson-johnsons-talc-litigation-bankruptcy-bid-is-ba" rel="noreferrer noopener">Justice Department&#8217;s Trustee Program Alleges Johnson &amp; Johnson&#8217;s Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability</a>
As a result, the company has no plans to settle and will reverse about $7 billion previously <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40398448/johnson-johnson-nears-approval-for-6-5b-long-standing-talc-settlement" rel="noreferrer noopener">set aside for legal costs</a>.
&#8220;The Court has unfortunately allowed a couple of law firms with financially conflicted motives, who have conceded they have not recovered a dime for their clients in a decade of litigation, to defeat the overwhelming desire of claimants. As we have repeatedly stated, in the absence of plan confirmation, we will vigorously present our case in the tort system, starting with the adjudication of the motions pending in the Multi-District Litigation to exclude plaintiffs&#8217; experts and to disqualify the lead counsel for its unethical breaches,&#8221; said Erik Haas, Worldwide VP of Litigation, Johnson &amp; Johnson. &#8220;We prevailed in 16 of 17 ovarian cases tried in the last 11 years and will devote our efforts to defeating these fake claims.&#8221;
&#8220;Today&#8217;s decision highlights the broken tort system in the United States. The company reiterates that none of the talc-related claims against it have merit and attempts to resolve this litigation were aimed at moving past this issue,&#8221; Haas continued. &#8220;The decision to litigate every filed case is based on the simple fact that this is a fake claim created by greedy plaintiff lawyers looking for another deep pocket to sue and fueled by litigation-financed attorney advertising.&#8221;
In September,&nbsp;Johnson &amp; Johnson&nbsp;reportedly increased its settlement offer by $1 billion, now totaling about $9 billion, to address claims that its talc baby powder&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40738358/johnson-johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory" rel="noreferrer noopener">caused gynecological cancer</a>.
Price Action: JNJ stock is down 3.48% at $160.07 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44582215/chinas-xpeng-clocks-record-q1-ev-sales-deliveries-surge-3-6x" target="_blank" rel="noreferrer noopener">China&#8217;s XPeng Clocks Record Q1 EV Sales, Deliveries Surge 3.6X</a></li>
</ul>
Photo: Shutterstock

Legal

US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims

<ul>
<li>Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years</li>
<li>Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution</li>
</ul>

Reported Earlier, Johnson & Johnson Shifts Focus Back To Tort System, Will Litigate Talc Claims After Bankruptcy Court Denial

If you&#8217;ve been paying attention to the stock market recently, you must have come across a rather unexpected turn of events—value stocks are taking center stage from their flashy growth rivals. Over the course of three months, the Russell 1000 Value Index has <a href="https://www.benzinga.com/general/market-summary/25/03/44555763/value-stocks-are-crushing-growth-superstars-in-2025-is-more-to-come">beaten the Russell 1000 Growth Index </a>by a healthy 11%. That&#8217;s a far cry from this time last year, when tech and AI plays were driving the market upwards.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/03/44569468/growth-or-value-allsprings-new-etfs-offer-both">Growth Or Value? Allspring&#8217;s New ETFs Offer Both</a>
With tariffs, geopolitical tensions, and recession jitters swirling, investors are flocking to the relative safety of value stocks. But is it a permanent pivot, or a temporary sidetrack? Although no one knows for sure what the market will do, history suggests that value stocks have a way of surviving rough patches.
For those looking to ride the wave, these <a href="https://www.benzinga.com/etfs">four value-based ETFs</a> are worth considering:
iShares Russell 1000 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWD#NYSE">IWD</a>)
The first choice for most investors seeking to follow the Russell 1000 Value Index, IWD offers broad exposure to large-cap value stocks from a wide range of sectors, such as financials, healthcare, and consumer staples. Some of its holdings include stocks of JP Morgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>). With its size and liquidity, this ETF is a convenient means of achieving diversified exposure to the value sector. It carries an expense ratio of 0.19%.
Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>)
An affordable fund with a bottom-of-the-barrel expense ratio of 0.04%, VTV tracks the CRSP US Large Cap Value Index. Blue-chip stalwarts such as JPMorgan Chase, and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are overweights in this fund, which is a good bet for stability and long-term growth.
SPDR S&amp;P 500 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPYV#NYSE">SPYV</a>)
If you desire exposure to value stocks as part of the larger S&amp;P 500, SPYV may be considered. This ETF targets S&amp;P 500 stocks that reflect strong value features in terms of low price-to-earnings and price-to-book ratios. With the valuation differential between value and growth stocks as high as it is now, this ETF is poised to profit from a possible market correction. The portfolio is similar to that of IWD and VTV, and the expense ratio is 0.04%.
Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)
Dividend stocks tend to overlap with value stocks, and SCHD is a good representative of this case. Concentrating on high-grade dividend-paying businesses, this ETF not only gets investors exposed to value stocks but also provides a steady income under market uncertainty. Its portfolio carries blue-chip brands such as Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). This ETF comes with an expense ratio of 0.06%.
Also Read: <a href="https://www.benzinga.com/25/03/44570070/tariffs-inflation-and-tumbling-markets-these-5-etfs-thrived-amid-the-chaos-last-week">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a>
Why Value Could Stay On Top
Last quarter&#8217;s value outperformance is more than just jitters in the market. It&#8217;s because, as BlackRock&#8217;s Global CIO of Fundamental Equities Tony DeSpirito <a href="https://www.blackrock.com/us/individual/insights/value-stocks-underweight-and-unaware?utm_source=chatgpt.com">says</a>, growth stocks now comprise almost 40% of the S&amp;P 500—more than double their long-term average of 24%. With the valuations pulled forward, investors might begin shifting into value stocks for diversification. In addition, sectors like utilities, health care, and materials—staples in value indexes—are less tariff-vulnerable and potentially even positively affected by changes in trade policy.
While growth stocks may recover over time, the current market environment has favored value stocks. For those interested in exploring this trend, these four ETFs offer examples of funds that focus on value investing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/03/44570028/westwoods-new-bfre-etf-prioritizes-democracy-over-autocracy">Westwood&#8217;s New BFRE ETF Prioritizes Democracy Over Autocracy</a></li>
</ul>
Photo: Shutterstock

SPYV

Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend

MRNA

President Trump Says Will Be Announcing Pharma Tariffs Soon

Press Releases

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

Management

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

TVGN

TVGNW

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

RBC Capital

B of A Securities

Barclays

Morgan Stanley

Stifel

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) Opciones

Johnson & Johnson (NYSE:JNJ) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL